Der Onkologe

, Volume 11, Issue 9, pp 942–947 | Cite as

Behandlung fortgeschrittener Stadien des Hodgkin-Lymphoms

Leitthema

Zusammenfassung

Die Prognose für Patienten mit Hodgkin-Lymphom hat sich in den letzten 30 Jahren erheblich verbessert. In Abhängigkeit von dem Stadium bei Erstdiagnose können mittlerweile Heilungsraten von über 80% erzielt werden. Moderne Therapiestrategien sollen insbesondere das Auftreten von therapiebedingten Spätfolgen bei gleichzeitiger Beibehaltung der guten Tumorkontrolle verringern. Offene Fragen in den fortgeschrittenen Stadien betreffen die optimale Zyklusanzahl bei einer effektiven Chemotherapie und die Notwendigkeit einer zusätzlichen Bestrahlung. Der Stellenwert der PET bezüglich der Unterscheidung zwischen residualen narbigen Veränderungen und aktivem Lymphomgewebe nach intensiver Chemotherapie wird in der aktuellen Studie (HD15) untersucht.

Schlüsselwörter

Hodgkin-Lymphom Fortgeschrittene Stadien Chemotherapie Radiotherapie 

Treatment of advanced stage Hodgkin’s lymphoma

Abstract

High cure rates have been achieved in the treatment for patients with Hodgkin’s lymphoma (HL) in the past 30 years. Depending on stage at diagnosis, more than 80% of patients can be cured with first-line treatment. Modern therapeutic strategies aim at both reducing therapy-induced late toxicities while maintaining effective tumor control. Questions to be answered in the treatment of advanced stages concern the optimal number of cycles for an effective chemotherapy regimen and the necessity for additional radiation therapy. The role of PET in differentiating between residual scar tissue and active lymphoma is being evaluated in the ongoing trial (HD15).

Keywords

Hodgkin’s Lymphoma Advanced-stages Chemotherapy Radiotherapy 

Literatur

  1. 1.
    Aleman BM, Raemaekers JM, Tirelli U et al. (2003) Involved-field radiotherapy for advanced Hodgkin’s lymphoma. N Engl J Med 348:2396–406Google Scholar
  2. 2.
    Bonadonna G, Zucali R, Monfardini S et al. (1975) Combination chemotherapy of Hodgkin‘s disease with adriamycin, bleomycin, vinblastine, and imidazole carboximide versus MOPP. Cancer 36:252–259Google Scholar
  3. 3.
    Canellos GP, Anderson JR, Propert KJ et al. (1992) Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327:1478Google Scholar
  4. 4.
    Connors JM, Klimo P, Adams G et al. (1997) Treatment of advanced Hodgkin‘s disease with chemotherapy — comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: A report from the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 15:1638–1645Google Scholar
  5. 5.
    de Wit M, Bohuslavizki KH, Buchert R et al. (2001) 18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin’s lymphoma. Ann Oncol 12:29–37Google Scholar
  6. 6.
    Diehl V, Franklin J, Pfreundschuh M et al. (2003) Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease. N Engl J Med 348:2386–2395Google Scholar
  7. 7.
    Diehl V, Brillant C, Franklin J et al. (2004) BEACOPP chemotherapy for Advanced Hodgkin’s Disease: Results of Further Analyses of the HD9- and HD12- Trials of the German Hodgkin Study Group (GHSG). Blood 104 A: 307Google Scholar
  8. 8.
    Duggan DB, Petroni GR, Johnson JL et al. (2003) Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin’s disease: report of an intergroup trial. J Clin Oncol 21:607–614Google Scholar
  9. 9.
    Goldie JH, Coldman AJ (1979) A mathematical model for relating the drug sensitivity of tumors to the spontaneous mutation rate. Cancer Treat Rep 63:1727–1733Google Scholar
  10. 10.
    Hasenclever D, Diehl V (1998) A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin’s Disease. N Engl J Med 339:1506–1514Google Scholar
  11. 11.
    Loeffler M, Brosteanu O, Hasenclever D et al. (1998) Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin’s disease. International Database on Hodgkin’s Disease Overview Study Group. J Clin Oncol 16:818–829Google Scholar
  12. 12.
    Longo DL, Young RC, Wesley M et al. (1986) Twenty years of MOPP chemotherapy for Hodgkin‘s disease. J Clin Oncol 4:1295–1306Google Scholar
  13. 13.
    Santoro J, Bonadonna G, Valagussa P et al. (1987) Long-term results of combined chemotherapy–radiotherapy approach in Hodgkin’s disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol 5:27Google Scholar
  14. 14.
    Sieber M, Bredenfeld H, Josting A et al. (2003) 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin’s lymphoma: results of a pilot study of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 21:1734–1739Google Scholar
  15. 15.
    Sieber M, Tesch H, Pfistner B et al. (2004) Treatment of advanced Hodgkin’s disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: final results of the German Hodgkin’s Lymphoma Study Group HD6 trial. Ann Oncol 15:276–282Google Scholar
  16. 16.
    Viviani S, Bonadonna G, Santoro A et al. (1996) Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin‘s Disease: Ten-year results. J Clin Oncol 14:1421–1430Google Scholar
  17. 17.
    Weihrauch MR, Re D, Scheidhauer K et al. (2001) Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood 98:2930–2934Google Scholar

Copyright information

© Springer Medizin Verlag 2005

Authors and Affiliations

  1. 1.Klinik I für Innere Medizin, Universität zu Köln
  2. 2.Klinik I für Innere Medizin, Universität zu Köln Köln

Personalised recommendations